Risk of cholangiocarcinoma in patients undergoing therapeutic endoscopic retrograde cholangiopancreatography or cholecystectomy: A population based study

Table 2 The comparisons of cholelithiasis patients underwent therapeutic endoscopic retrograde cholangiopancreatography, cholecystectomy or no intervention

	ES/EPBD n = 537		Cholecystectomy n = 1743		Without intervention n = 5658		P value
	N	SD, %	N	SD, %	N	SD, %
Age, mean (SD)	64.33	16.33	56.95	16.53	59.34	16.43	0.941
Age, yr
18-49	39.29	7.59	38.26	7.6	39.09	7.27	0.391
50-69	60	5.2	59.3	5.56	58.99	5.53	0.559
> 70	79.11	5.73	78.01	5.54	78.78	6.08	0.002
Gender							0.692
Male	264	49.16	843	48.36	2691	47.56
Female	273	50.84	900	51.64	2967	52.44
Follow up time (mo), mean (SD)	56.3	22.24	61.38	18.4	56.88	22.27	< 0.001
Economic status							0.16
MBS	319	59.4	1137	65.23	3590	63.45
1-3 times MBS	209	38.92	574	32.93	1964	34.71
Above 3 times MBS	9	1.68	28	1.61	94	1.66
Place of residence							0.009
City	296	55.12	854	49	2813	49.72
Countryside	205	38.18	681	39.07	2250	39.77
Remote village	36	6.7	204	11.7	585	10.34
Comorbidity
CHB	50	9.31	137	7.86	567	10.02	0.026
CHC	22	4.1	73	4.19	447	7.9	< 0.001
HP	11	2.05	23	1.32	94	1.66	0.433
DM	167	31.1	478	27.42	1674	29.59	0.135
ESRD	12	2.23	37	2.12	137	2.42	0.76
CCDL	13	2.42	12	0.69	26	0.46	< 0.001
CO	0	0	0	0	0	0	NA
IBD	6	1.12	23	1.32	90	1.59	0.54
Cholangiocarcinoma
Number of cholangiocarcinoma	27	5.03	15	0.86	105	1.86	< 0.001
Number of cholangiocarcinoma after first 6 mo	11	2.05	7	0.4	37	0.65	< 0.001
Odds ratio	3.13		0.61		1
Number of cholangiocarcinoma after first 12 mo	10	1.86	6	0.34	35	0.62	< 0.001
Odds ratio	3.01		0.56		1
Time to diagnosis of cholangiocarcinoma (excluding case in initial 6 mo), month	41.17	22.51	33.7	23.35	35.46	19.08	0.698

SD: Standard deviation; MBS: Minimum basic salary; CHB: Chronic hepatitis B; CHC: Chronic hepatitis C; HP: Helicobacter infection; DM: Diabetes mellitus; ESRD: End-stage renal disease; CCDL: Congenital cystic disease of liver; CO: Clonorchis Opisthorchis; IBD: Inflammatory bowel disease.